Debjani Taraphdar¹*, Ranjana Hawaldar¹ and Sadhna Sodani²

¹1Sampurna Sodani Diagnostic Clinic, Indore, India

*Corresponding Author: Debjani Taraphdar, Consultant, Molecular Biology, Sampurna Sodani Diagnostic Clinic, Indore, India.

Received: November 18, 2022; Published: December 12, 2022

Abstract

Background: Detection of human papilloma virus (HPV) infection and its genotype distribution are much-needed parameters to judge the risk of cervical cancer among females. However, due to less availability of data on HPV burden in Central part of India makes cervical cancer screening difficult.

Methods: A total of 270 participants had been tested for abnormalities in cytology (Pap smear) and real-time PCR was performed for HPV DNA detection.

Result: The most common cytological finding among HPV positive patients was found to be of negative for intraepithelial lesion or malignancy NILM (93.7%), followed by atypical squamous cells of undetermined significance (ASCUS) (5.2%), low-grade intraepithelial lesion (LSIL) (0.7%) and high-grade intraepithelial lesion (0.35%) cases. HPV DNA was detected in (8.1%) patients. Highest positivity was seen in the age group of 30-39 years followed by age group of 20-29 years. The most common HPV type in our study was HPV 16 (45.4%) followed by HPV 31 infection (27.2%). Other genotypes of HPV found were HPV18 (13.6%), HPV 51 (2; 9%), HPV 58 (2; 9%), and HPV 39 or 68∗ (9%). 

Conclusion: It is evident from our study that HPV DNA infection was observed with normal cervical cytology. For early detection both Pap smear and HPV DNA genotype detection should be the choice for preventing cervical cancer in women.

Keywords: Human Papilloma Virus; Genotype; Cytological Abnormalities; High Risk; Central India

References

1. Jacob M. “Information, education and communication: Corner stone for preventing cancer of the cervix”. Indian Journal of Medical Research 136 (2012): 182-4.
2. Ferlay J., et al. “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”. International Journal of Cancer 127 (2010): 2893-2917.
3. National Cancer Registry Programme. “Time trends and cancer incidence rates: 1982-2005”. Bangalore: National Cancer Registry Programme; (2009).
4. World Health Organization. “Comprehensive cervical cancer control: A guide to essential practice”. Geneva: WHO; (2006): 32-49.
5. Das BC., et al. “Human papillomavirus DNA in urine of women with preneoplastic and neoplastic cervical lesions”. Lancet 340 (1992): 1417-1418.
6. Hussain S., et al. “Human papillomavirus infection among young adolescents in India: Impact of vaccination”. Journal of Medical Virology 84 (2012): 298-305.
7. Hausen H., et al. “Attempts to detect virus-specific DNA in human tumors. II. Nucleic acid hybridizations with complementary RNA of human herpes group viruses”. International Journal of Cancer 13 (1974): 657-664.
8. Duensing S., et al. “Human papillomaviruses and centrosome duplication errors: Modeling the origins of genomic instability”. Oncogene 21 (2002): 6241-6248. 
9. Das BC., et al. “Prospects and prejudices of human papillomavirus vaccines in India”. Vaccine 26 (2008): 2669-2679.
10. Basu P., et al. “Human papillomavirus genotype distribution in cervical cancer in India: Results from a multi-center study”. Asian Pacific Journal of Cancer Prevention 10 (2009): 27-34.
11. Cervical cancer, World Health Organisation.
12. Gupta S., et al. “Burden and Associated Genotype Patterns of High-Risk Human Papilloma Virus Infection and Cervical Cytology Abnormalities among Women in Central India”. Infectious Diseases in Obstetrics and Gynecology (2022): 7.
13. Maheshwari S., et al. “Prevalence and distribution of various human papillomavirus genotypes in women with high risk for cervical carcinoma”. International Journal of Reproduction, Contraception, Obstetrics and Gynecology 9 (2020): 2498-2503.
14. Sharma P., et al. “Significance of Human Papilloma Virus genotyping in cervical cancer screening”. Tropical Journal of Pathology and Microbiology 3 (2016): 120-124.
15. Zhang X., et al. “HPV Genotype Specific and Age Stratified Immediate Prevalence of Cervical Precancers and Cancers in Women with NILM/hrHPV+: A Single Center Retrospective Study of 26,228 Cases”. Cancer Management Research 13 (2021): 6869-6877^.
16. Park E., et al. “Carcinogenic risk of human papillomavirus [HPV] genotypes and potential effects of HPV vaccines in Korea”. Scientific Reports 9 (2019): 12556.
17. Sekri E., et al. “Prevalence of Cytological Abnormalities in Papanicolaou Smears and Risk Factors for Cervical Cancer Among Women in Muscat, Oman”. Sultan Qaboos University Medical Journal4 (2021): 598-603.
18. Bayram A., et al. “Prevalence of high-risk human papillomavirus in women from Turkey”. Clinical Obstetrics, Gynecology and Reproductive Medicine 3 (2015) 84-86.
19. Domingoa EJ., et al. “Epidemiology and Prevention of Cervical Cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam”. Vaccine 12 (2008): M71-M79.
20. Basu P., et al. “Human papillomavirus genotype distribution in cervical cancer in India: Results from a multi-center study”. Asian Pacific Journal of Cancer Prevention 10 (2009): 27-344.
21. Mane A., et al. “HPV genotype distribution in cervical intraepithelial neoplasia among HIV-infected women in Pune, India”. PLoS One6 (2012): e38731.
22. Banerjee P., et al. “Human papillomavirus (HPV) prevalence in relation with cervical cytology in Bengali population of India”. medRxiv (2020).
23. Pillai RM., et al. “Region-wise distribution of high-risk human papillomavirus types in squamous cell carcinomas of the cervix in India”. International Journal of Gynecological Cancer 20 (2010): 1046-1051.
24. Wang, Z., et al. “Risk of cervical lesions in high-risk HPV positive women with normal cytology: a retrospective single-center study in China”. Infectious Agents Cancer34 (2020).
25. Bhattacharya A., et al. “Prevalence and age-wise distribution of Human Papillomavirus type 16/18 infections among hospital screened women of a peri-urban area in West Bengal: Impact of socio-demographic factors”. Cancer Epidemiology 54 (2018): 31-37.
26. Mishra R., et al. “Distribution and Prevalence of High-risk Human Papillomavirus Infection in Women of Western Uttar Pradesh, India: A Hospital-based Study”. Journal of South Asian Federation of Obstetrics and Gynaecology2 (2022).
27. Polman NJ., et al. “HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test”. British Journal of Cancer10 (2017): 1557-1561.
28. Liu G., et al. “HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer”. AIDS6 (2018): 795-808.
29. Senapati R., et al. “HPV Genotypes distribution in Indian women with and without cervical carcinoma: Implication for HPV vaccination program in Odisha, Eastern India”. BMC Infectious Diseases 17 (2017): 30.
30. Park E., et al. “Carcinogenic risk of human papillomavirus [HPV] genotypes and potential effects of HPV vaccines in Korea”. Scientific Report 9 (2019): 12556.
31. Muwonge R., et al. “Acquisition, prevalence and clearance of typespecific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study”. PLoS ONE12 (2020).

Citation

Citation: Debjani Taraphdar., et al. “Prevalence and Distribution of High-risk Human Papilloma Virus in Cervical Lesions and Asymptomatic Healthy Subjects of Central India". Acta Scientific Microbiology 6.1 (2023): 09-14.

Copyright

Copyright: © 2022 Debjani Taraphdar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.